A patient on prednisone 80 mg daily and NPH insulin 17 units with a carbohydrate‑to‑insulin ratio of 1 unit per 5 g carbohydrate will reduce prednisone to 70 mg and start tirzepatide (Mounjaro); what should the NPH insulin dose and carbohydrate‑to‑insulin ratio be adjusted to?

NPH Dose and Carb Ratio Adjustment

Reduce NPH to approximately 15 units and maintain the carbohydrate ratio at 1:5 initially, with close monitoring for further adjustments as tirzepatide is titrated up.

Rationale for NPH Dose Reduction

Impact of Prednisone Reduction (80 mg → 70 mg)

The 10 mg reduction in prednisone (12.5% decrease) warrants a modest insulin reduction. For steroid-induced hyperglycemia, NPH is typically dosed in the morning to match the peak hyperglycemic effect of intermediate-acting steroids like prednisone, which peaks 4-6 hours after administration 1, 2.

• A 10-20% reduction in insulin dose is recommended when reducing steroid doses without clear hypoglycemia 3
• This translates to reducing NPH by approximately 2 units (from 17 to 15 units)

Impact of Adding Tirzepatide (Mounjaro)

Tirzepatide significantly increases hypoglycemia risk when combined with insulin 4. The FDA label explicitly warns: "Patients receiving MOUNJARO in combination with an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia."

Key considerations:

• When adding GLP-1 receptor agonists (tirzepatide is a dual GIP/GLP-1 agonist) to basal insulin, insulin dose reduction is typically necessary 3
• In the SURPASS-6 trial, tirzepatide reduced total daily insulin requirements by approximately 24 units/day compared to prandial insulin when added to basal insulin 5
• Tirzepatide reduces HbA1c by 0.4-2.1% depending on dose 6, 5

Specific Dosing Recommendations

NPH Insulin Adjustment

Start with 15 units NPH (approximately 12% reduction from baseline):

• This accounts for the prednisone reduction (10-20% decrease recommended) 3
• Provides buffer against hypoglycemia as tirzepatide is initiated 4
• Administer NPH in the morning to match prednisone's hyperglycemic pattern 3, 1

Further reductions will likely be needed:

• As tirzepatide is titrated from 2.5 mg → 5 mg → higher doses over subsequent weeks, expect to reduce NPH by an additional 10-20% 3
• Monitor fasting glucose closely; if consistently <100 mg/dL, this predicts next-day hypoglycemia and warrants dose reduction 1

Carbohydrate Ratio

Maintain 1:5 ratio initially (1 unit per 5 grams carbohydrate):

• Tirzepatide's primary effect is on basal glucose control and weight loss, with less direct impact on prandial insulin sensitivity initially 5, 7
• Reassess after 2-4 weeks as tirzepatide reaches steady state
• Expect to liberalize the ratio (e.g., 1:6 or 1:7) as tirzepatide's full effects emerge, particularly if gastrointestinal side effects reduce food intake 4, 5

Monitoring and Titration Algorithm

1. Week 1-4 (Tirzepatide 2.5 mg):

   • NPH: 15 units morning
   • Carb ratio: 1:5
   • Check fasting glucose daily; if <100 mg/dL, reduce NPH by 2 units 1

2. Week 5-8 (Tirzepatide 5 mg):

   • Reduce NPH by additional 10-15% (to ~13 units) if glucose control adequate 3
   • Consider adjusting carb ratio to 1:6 if experiencing hypoglycemia post-meals

3. Week 9+ (Tirzepatide ≥7.5 mg):

   • May need NPH reduction to 10-12 units or less 5
   • Carb ratio may need adjustment to 1:6 or 1:7

Critical Pitfalls to Avoid

• Do NOT wait for hypoglycemia to reduce insulin – be proactive given tirzepatide's potent glucose-lowering effects 4
• Gastrointestinal side effects (nausea, vomiting) occur in 14-26% with tirzepatide and may reduce carbohydrate intake, necessitating further insulin reductions 4, 5
• Prednisone causes afternoon/evening hyperglycemia – if switching to bedtime NPH, expect worse control; morning dosing is preferred 1, 2
• Monitor for hypoglycemia <54 mg/dL – tirzepatide reduces this risk compared to prandial insulin (0.4 vs 4.4 events/patient-year), but risk remains with NPH 5